Fransgaard Tina, Hallas Jesper, Thygesen Lau Caspar, Gögenur Ismail
Department of Surgery, Zealand University Hospital, Køge, Denmark
Clinical Pharmacology and Pharmacy, University of Southern Denmark, Odense, Denmark.
Anticancer Res. 2019 Apr;39(4):2177-2182. doi: 10.21873/anticanres.13332.
The aim of the study was to examine if statin exposure during neoadjuvant chemoradiotherapy improves oncological outcomes in patients with rectal cancer.
The study cohort consisted of patients who were undergoing neoadjuvant chemoradiotherapy and resection for rectal cancer. The statin users were matched 1:1 with non-users using propensity score-based matching. The primary outcome of the study was disease-free survival; secondary outcomes were recurrence-free survival and all-cause mortality.
A total of 704 patients were included in the study. Disease-free survival was not different between the two groups [hazard ratio (HR)=0.98, 95% confidence intervaI (CI)=0.77-1.25, p=0.88]. Both recurrence-free survival (HR=1.02, 95% CI=0.74-1.39, p=0.92) and all-cause mortality (HR=0.92, 95% CI=0.68-1.23, p=0.56) were similar for the two groups.
The study does not support that statin use is associated with response to neoadjuvant chemoradiotherapy in terms of disease-free survival, recurrence-free survival or all-cause mortality.
本研究旨在探讨新辅助放化疗期间使用他汀类药物是否能改善直肠癌患者的肿瘤学结局。
研究队列包括接受直肠癌新辅助放化疗及手术切除的患者。使用基于倾向评分匹配的方法，将他汀类药物使用者与非使用者按1:1进行匹配。本研究的主要结局是无病生存期；次要结局是无复发生存期和全因死亡率。
本研究共纳入704例患者。两组间无病生存期无差异[风险比（HR）=0.98，95%置信区间（CI）=0.77 - 1.25，p = 0.88]。两组的无复发生存期（HR = 1.02，95% CI = 0.74 - 1.39，p = 0.92）和全因死亡率（HR = 0.92，95% CI = 0.68 - 1.23，p = 0.56）均相似。
就无病生存期、无复发生存期或全因死亡率而言，本研究不支持使用他汀类药物与新辅助放化疗反应相关。
